Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

PXDNL Inhibitors

PXDNL Inhibitors represent a category of chemical compounds that target the enzyme PXDNL, also known as Peroxidasin-like protein. This enzyme is a member of the peroxidase family, which are enzymes responsible for catalyzing the oxidation of a variety of substrates in the presence of hydrogen peroxide. PXDNL, like other peroxidases, contains a heme moiety that allows it to partake in electron transfer reactions, thus facilitating its catalytic activity. As the name suggests, PXDNL shares similarities with the peroxidasin protein, but they each have distinct functions within cells. PXDNL inhibitors are designed to specifically interrupt the activity of this enzyme, without significantly affecting the functions of other peroxidases or related enzymes.

The significance of inhibiting PXDNL arises from its involvement in various biochemical processes within cells. While the exact role of PXDNL in these processes remains an active area of research, it is clear that its enzymatic activity can influence cellular pathways and contribute to certain physiological phenomena. Given its specificity and selectivity, PXDNL inhibitors offer a means to probe the function of this enzyme in various cellular contexts. By blocking the activity of PXDNL, researchers can get a clearer picture of its role in these pathways. The design and synthesis of PXDNL inhibitors involve a deep understanding of the enzyme's active site, its interaction with substrates, and the structural aspects that can be targeted to reduce or eliminate its activity.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits the tyrosine kinase activity of BCR-ABL, blocking cell signaling in chronic myeloid leukemia.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets multiple kinases, including RAF and VEGFR, suppressing angiogenesis and cell proliferation in cancer.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Irreversibly inhibits BTK, a critical enzyme in B-cell signaling, leading to suppression of B-cell malignancies.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Blocks the EGFR tyrosine kinase, disrupting downstream signaling pathways and halting tumor growth in NSCLC.

MDV3100

915087-33-1sc-364354
sc-364354A
5 mg
50 mg
$245.00
$1051.00
7
(1)

Acts as an androgen receptor antagonist, inhibiting androgen binding and signaling in prostate cancer.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$210.00
$305.00
$495.00
10
(1)

PARP inhibitor that disrupts DNA repair in BRCA-mutated cells.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

Specifically inhibits BRAF V600E mutant kinase, impairing MAPK signaling and halting growth in melanoma.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor that suppresses cytokine signaling.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dual Src and BCR-ABL inhibitor, blocking kinase activities and mitigating the progression of CML and other cancers.